

1 **Bacterial and Fungal Co-Infections among ICU COVID-19 Hospitalized Patients in**  
2 **a Palestinian Hospital: Incidence and Antimicrobial Stewardship.**

3  
4 **Hani Naseef, Ula Mohammad, Nimeh Al-Shami, Yousef Sahoury, Abdallah D. Abukhalil, Mohammad**  
5 **Farraj**

6 **Hani A. Naseef**, PhD , Associate professor, Pharmacy Department, Faculty of Pharmacy, Nursing and  
7 Health Professions, Birzeit University, Palestine ([hshtaya@birzeit.edu](mailto:hshtaya@birzeit.edu) ), P.O. Box 14, Birzeit, West Bank,  
8 Palestine

9 **Ula Mohammad, PharmD** Department of Pharmacy, Faculty of Pharmacy, Nursing and Health Professions,  
10 Birzeit University, Palestine ([hashemula18@gmail.com](mailto:hashemula18@gmail.com)), P.O. Box 14, Birzeit, West Bank, Palestine

11 **Nimeh Al-Shami**, MPH., Pharmacy Department, Faculty of Pharmacy, Nursing and Health Professions,  
12 Birzeit University, Palestine ([nemaashami86@gmail.com](mailto:nemaashami86@gmail.com) ), P.O. Box 14, Birzeit, West Bank, Palestine

13 **Yousef Sahoury**, Department of Pharmacy, Faculty of Pharmacy, Nursing and Health Professions, Birzeit  
14 University, West Bank, State of Palestine, email: [sahoury1987@yahoo.com](mailto:sahoury1987@yahoo.com)

15 **Abdallah D. Abukhalil, PhD** , Pharmacy Department, Faculty of Pharmacy, Nursing and Health  
16 Professions, Birzeit University, Palestine ([adkhalil@birzeit.edu](mailto:adkhalil@birzeit.edu)), P.O. Box 14, Birzeit, West Bank, Palestine

17 **Mohammad Farraj**, Associate professor, Master Program in Clinical Laboratory Science, Faculty of  
18 Pharmacy, Nursing and Health Professions, Birzeit University, West Bank, State of Palestine, email:  
19 [mfarraj@birzeit.edu](mailto:mfarraj@birzeit.edu)

20  
21  
22

23

24

25

26

27

28

29 **Abstract:** Diagnosis of co-infections with multiple pathogens among hospitalized COVID-19  
30 patients can be jointly challenging and very essential for appropriate treatment, shortening

31 hospital stay and preventing antimicrobial resistance. This study proposes to investigate the  
32 burden of bacterial and fungal co-infections outcomes on COVID-19 patients. It is a single centre  
33 cross-sectional study of hospitalized COVID-19 patients at Beit-Jala hospital in Palestine. The  
34 study included 321 hospitalized patients admitted to the ICU between June 2020 and March 2021  
35 aged  $\geq 20$  years, with a confirmed diagnosis of COVID-19 via RT-PCR conducted on a  
36 nasopharyngeal swab. The patient's information was gathered using graded data forms from  
37 electronic medical reports. The diagnosis of bacterial and fungal infection was proved through  
38 the patient's clinical presentation and positive blood or sputum culture results. All cases had  
39 received empirical antimicrobial therapy before the ICU admission, and different regimens during  
40 the ICU stay. The rate of bacterial co-infection was 51.1%, mainly from gram-negative isolates  
41 (Enterobacter species and K.pneumoniae). The rate of fungal co-infection caused by A.fumigatus  
42 was 48.9%, and the mortality rate was 8.1%. However, it is unclear if it had been attributed to  
43 SARS-CoV-2 or coincidental.

44 **Key words:** COVID 19, Co-infection, Palestine, Iron supplements, ICU.

45

46

47

48

49

50

51 **Introduction**

52 Severe Acute Respiratory Syndrome Coronavirus 2 (SAR-CoV-2) is a highly contagious novel viral  
53 pathogen that provokes an immediate spread among hospitalized patients with Community-  
54 Acquired Pneumonia (CAP) (1); extending from mild symptoms approximately in 84% of patients  
55 to life-threatening hypoxic conditions necessitating admittance into the Intensive Care Unit (ICU)  
56 and oxygen support (2). Additionally, it causes multi-organ failure that involves sepsis and  
57 thromboembolic complications, which progresses into an acute kidney and cardiac injury (3). On  
58 March 11<sup>th</sup>, 2020, the World Health Organization (WHO) deemed COVID-19 a pandemic disease;  
59 due to its unusual transmission speed and the wide-scale of infection (4).

60 The bacterial and fungal co-infections are frequently recurring due to respiratory viral diseases.  
61 For example, most deaths in the Spanish flu pandemic in 1918 were due to subsequent bacterial  
62 infection (5). It raises a concern as it hinders COVID-19 management, worsens prognosis, and  
63 might increase the fatality rate. The reported prevalence of bacterial co-infection varies between  
64 studies (6).

65 Throughout the pandemic, evaluation of gathered specimens from hospitalized COVID-19  
66 patients reported the most prevalent organisms, which induce the co-bacterial infection; these  
67 were *S. aureus*, *S. epidermidis*, *H. influenzae*, *Streptococcus* spp., *E. coli*, *K. pneumoniae* and *P.*  
68 *aeruginosa* (7). Therefore, many COVID-19 treatment protocols include empirical antibiotic  
69 therapy to cover suspected organisms. Relatively, in a systematic review, thirty studies were  
70 summarized including 3834 COVID-19 patients. Overall only 7% of the hospitalized patients were  
71 confirmed to have bacterial co-infection with one or more pathogens, primarily in seriously ill  
72 patients (8). On the contrary, fungus infections in COVID-19 patients are neglected or delayed

73 and were elusive to have the actual prevalence of fungal co-infection and yet to be explained in  
74 extent. Few studies were conducted in this regard; a systematic review meta-analysis research  
75 was carried out in China on 2780 confirmed SAR-CoV-2 participants from nine relevant articles.  
76 After fungal culturing at admission, 0.12%- 0.15% of the cases were positive for fungal infection  
77 and Asian patients were more likely to acquire fungal co-infection. The infecting fungi include  
78 *Aspergillus*, *Candida*, *Cryptococcus neoformans*, *Pneumocystis*, or other fungal species (9).

79 The exact mechanism of microbial co-infection is inadequately understood. Virologists assumed  
80 that the viruses attach and penetrate the host's airway epithelial cells creating an inflammatory  
81 response desensitizing Toll-like receptors leading to cellular apoptosis in numerous mechanisms.  
82 In addition, it debilitates the body's defense, induces cellular dysfunction and death (10).

83 Viruses aid in proliferation, colonization, and invasive infection of opportunistic nosocomial  
84 pathogen or respiratory tract normal flora; via hindering the innate immune response,  
85 compressing airway mucus, and disrupting the cilia. Thereby, this will allow for the spread and  
86 adhesion to more sites (3). Furthermore, various researches highlighted the synergy regulations  
87 among viruses and bacteria; both are jointly advantageous, aggravating clinical outcomes. If this  
88 cooperation is confirmed, then the management with antibiotics becomes further reasonable  
89 (11).

90 The COVID-19 disease has been chiefly linked to high levels of inflammatory markers, such as  
91 elevated levels of C-reactive protein and procalcitonin. Accordingly, the similarity between Sar-  
92 CoV-2 and bacterial infections in radiological infiltrates and laboratory findings makes it  
93 challenging in daily medical practice to provide a precise diagnosis (12). However, according to

94 current studies, most COVID-19 patients did not have bacterial or fungal co-infections upon  
95 admission or through the hospital stay, even though they received antibiotics upon admission or  
96 before diagnosis (13). Furthermore, lack of specific antiviral agents and the overload to the  
97 health services capacity, saturated laboratories used to identify the causative microbial and  
98 diagnosis uncertainty to rule out super-infections; those factors advocated escalation of  
99 antimicrobial consumption in the pandemic (14). As a result, clinicians are obliged to prescribe  
100 broad-spectrum multi-antibiotic regimens; to treat all the possible infected pathogens.  
101 Therefore, this study aimed to investigate and evaluate bacterial and fungal co-infection burden  
102 and prevalence among COVID-19 patients admitted to a treatment facility at Beit-Jala hospital in  
103 Palestine. In addition, it reveals the etiology of the infection, provides the antimicrobial  
104 stewardship that was used in the hospital and gives insight into the association of clinical  
105 outcomes with several factors and comorbidities.

## 106 **Material and Methods**

### 107 **Study Design and Study Population**

108 This single-centre cross-sectional study was conducted on patients aged 20 years and older in  
109 Beit-Jala hospital, one of the central institutes for treating SAR-CoV-2 patients in Palestine. A total  
110 of 321 critically ill patients were admitted to the ICU between June 2020 and March 2021, with a  
111 confirmed diagnosis of COVID-19 via reverse transcriptase-polymerase chain reaction assay (RT-  
112 PCR) conducted on nasopharyngeal swab specimens. Only patients with positive cultures for  
113 bacteria or fungi were included in the study, and patients with negative cultures were excluded.  
114 The study was approved by the Scientific Research Ethics Committee of Birzeit University and by  
115 Beit-Jala hospital.

## 116 **Data Extraction and Analysis**

117 Data extraction was done manually and verified by a second researcher, using graded data forms  
118 from electronic medical reports. The obtained data were socio-demographics, chronic  
119 comorbidities, laboratory findings (CRP, Leukocytes, blood Oxygen saturation), duration of ICU  
120 stay and other factors. The bacterial or fungal co-infection was proved through clinical  
121 presentation and positive blood or sputum testing via Laboratory Information System. Before  
122 and during the ICU admission, antimicrobial utilization was recorded, and the reports were  
123 double-checked for accuracy and completeness.

124 The analysis was performed on these data and summarized socio-demographic and clinical  
125 characteristics using relevant descriptive statistics; categorical variables as percentages and  
126 frequencies. Then Pearson's Chi-square test was performed to determine the association  
127 between the main parameters, which were the ICU residency duration and the other factors such  
128 as; demographics, Iron supplements, antibiotics administration before and during the ICU  
129 admission and smoking habits, etc. Data was applied and presented upon the IBM Statistical  
130 Package for the Social Sciences version 22.0. (SPSS).

## 131 **Definitions**

132 Co-infection is a sequela that occurs during or after the primary causative pathogen or its  
133 treatment. The isolated bacteria or fungi obtained from COVID-19 patients should be clinically  
134 relevant and not microbiota or contaminants. All the microbiological samplings were conducted  
135 upon the hospital's entry and before the ICU admittance, and only patients holding positive  
136 bacterial or fungal outcomes were admitted into the unit. In combination with decision-making,  
137 a scope of standards should meet to provide permission on who necessitates access. Essentially,

138 Computerized Tomography (CT) scans revealing ground-glass opacification, which correlated  
139 with Pneumonia. In addition, supplementary laboratory outcomes were crucial in making the  
140 diagnosis, such as C-reactive protein (CRP) level, Oxygen saturation (SpO<sub>2</sub>), Leukocytes numbers  
141 and body temperature. Patients were immediately admitted to the ICU; if two or more of the  
142 above matched positive isolates test and CT-scan showing Pneumonia.

143 To determine the status of each patient, laboratory findings must be evaluated. For example, CRP  
144 values that ranged between 4.5-8.5 mg/dL were rated as moderate and  $\geq 8.5$  mg/dL and then  
145 rated as severe. Leukocytes results ranged within 4.6- 8 g/L was considered mild, while  $>8$  g/L  
146 indicates seriously ill patients. Normal Oxygen saturation of  $\geq 95\%$ , but in COVID-19 patients, the  
147 oximeter reading at rest of 90% or lower is a severe case. The body temperature is deemed high  
148 if it was 38- 39 °C and very high if it was  $>39$  °C.

## 149 **Results**

### 150 **Presenting Demographics**

151 A total of 321 moderate-severe ill patients were screened and evaluated. The patient`s  
152 demographics and clinical characteristics are presented in Table 1. Overall, 48.9% (170) were 41-  
153 64 years of age, 50.5% (162) were males. Prevailing chronic medical conditions included Diabetes  
154 Mellitus 77.9% (250), Atrial Hypertension 66.4% (213), Obesity 36.8% (118), Cancer 20.6% (66),  
155 Coronary Heart Disease 23.1% (74) and 3.7% of patients did not have personal clinical  
156 history. 58.6% were not smokers, and 62.6 % were supplemented with Iron 376 mg/day  
157 intravenously for three days. Further, all the participants in this study had received N-acetyl-  
158 cystine 1200 mg /day, which began from their hospital`s entrance to the exit.

159 **Bacterial and Fungal Co-Infection**

160 The overall mortality rate in this study was 8.1% (26), while 72.9% (234) of the patients remained  
161 in the ICU for 1-6 days. Each patient was infected with one type of bacteria or fungi; presented  
162 as respiratory infection, bacteremia, and skin infections. A total of six different pathogens were  
163 detected in the samplings and considered as the infecting organisms. The most abundant types  
164 were *Aspergillus fumigatus* 48.9% and *Enterobacter* 24.9%, as shown in Table 1

165 **Patterns of Antibiotic Use**

166 In terms of antibiotic prescription patterns, through the first 24h of hospital admission and based  
167 on per case specificity, the proper liver or kidney function tests had been conducted in all cases;  
168 to determine the appropriate regimen for bacterial or fungal infections. Before the ICU access,  
169 the treatment span was six days on average; 69.5% (223) received Ceftriaxone, and 30.5% (98)  
170 patients had received Ampicillin/ Sulbactam; both regimens were administered as intravenous  
171 dosing. Upon ICU admission, every patient had been given one kind of IV antibiotic regimen  
172 throughout the stay; 43.0% (138) took Meropenem and Vancomycin and 35.5% (114) given  
173 Piperacillin/ Tazobactam and Levofloxacin. By January and after getting financial support from  
174 the Ministry of Health, patients infected with *A.fumigatus* started therapy with Fluconazole,  
175 21.5% (69) were successfully treated. Considering different regimens had notable distinct  
176 outcomes, analysis was performed to determine the association linking antimicrobial therapy  
177 class and the ICU stay or death (Table2). After hospital discharge, patients taking antibacterial  
178 medications are switched to oral Azithromycin. Patients treated with Fluconazole IV for two days  
179 switched to oral Fluconazole 150mg/ week.



180 **Table 1: Demographics, Medical History and Antibiotic Regimens. (N 321)**

<b>Gender</b>	Male		162(50.5%)
	Female		159(49.5%)
<b>Age (Years)</b>	20-40		54 (16.8%)
	41-64		157(48.9%)
	>65		110(34.3%)
<b>Smoking Habits</b>	Yes		133(41.4%)
	No		188(58.6%)
<b>Presence of Comorbidities</b>	Diabetes Mellitus		250(77.9%)
	Atrial Hypertension		213(66.4%)
	Obesity		118(36.8%)
	Coronary Heart Disease		74 (23.1%)
	Cancer		66 (20.6%)
	No Personal History		12 (3.7%)
	CRP	Moderate	175(54.5%)
<b>Laboratory Findings on Day of ICU Admission</b>		High	146(45.5%)
	Leukocytes	Moderate	79 (24.6%)
		High	242(75.4%)
	SpO <sub>2</sub>	>90%	71 (22.1%)
	<90%	250(77.9%)	
<b>Microbiological Findings</b>	Fever	High	94 (29.3%)
		Very High	227(70.7%)
	A.fumigatus		157(48.9%)
	Enterobacter		80 (24.9%)
	K.pneumoniae		54 (16.8%)
	P.aeruginosa		10 (3.1%)
	VRE		10 (3.1%)
	S.aureus		9 (2.8%)
<b>Antibiotic Regimen Before Admittance Into The ICU</b>	Invalid Data		1 (0.3%)
	Ceftriaxone (2g/day)		223 (69.5%)
<b>Antibiotic Regimen During The ICU Stay</b>	Ampicillin/ Sulbactam (12g/day)		98 (30.5%)
	Meropenem+ Vancomycin (2g+ 1g/ day)		138 (43.0%)
	Piperacillin/ Tazobactam + Levofloxacin (13.5g+ 500mg/day)		114(35.5%)
	Fluconazole (200mg/day)		69 (21.5%)
<b>Iron Supplement [376 mg] Administration</b>	Yes		201(62.6%)
	No		120(37.4%)
<b>Duration of ICU Stay (days)</b>	1-6		234(72.9%)
	7-11		61 (19.0%)
	Death		26 (8.1%)

181

182 Table 2 reported that there was no significant association between the ICU stay duration with  
 183 age, laboratory test results or having a chronic disease. A significant association found between  
 184 the residency duration and SpO2 (P- value= 0.032), that patients whose SpO2 levels were <90%  
 185 (188:75.2%) were stayed for a shorter duration (1-6 days) at the ICU compared to patients with  
 186 SpO2 reads >90% (46: 64.8%).

187 **Table 2: Impact of Different Non-Significant Values on The duration in the ICU. (N 321)**

Parameter		Duration 1-6	Duration 7-11	Death	P value
		Days	Days		
<b>Age</b> <b>(years)</b>	<b>20-40</b>	41(75.9%)*	10(18.5%)	3(5.6%)	0.413
	<b>41-64</b>	119(75.8%)	28(17.8%)	10(6.4%)	
	<b>&gt;65</b>	74(67.3%)	23(20.9%)	13(11.8%)	
<b>Diabetes</b>	<b>Yes</b>	180(72.0%)	49(19.6%)	21(8.4%)	0.794
	<b>No</b>	54(76.1%)	12(16.9%)	5(7.0%)	
<b>Hypertension</b>	<b>Yes</b>	156(73.2%)	43(20.2%)	14(6.6%)	0.317
	<b>No</b>	78(72.2%)	18(16.7%)	12(11.1%)	
<b>Obesity</b>	<b>Yes</b>	81(68.6%)	25(21.2%)	12(10.2%)	0.383
	<b>No</b>	153(75.4%)	36(17.7%)	14(6.9%)	
<b>Smoking</b>	<b>Yes</b>	103(77.4%)	25(18.8%)	5(3.8%)	0.052
	<b>No</b>	131(69.7%)	36(19.1%)	21(11.2%)	
<b>CRP</b>	<b>Moderate</b>	128 (73.1%)	33 (18.9%)	14 (8.0%)	0.994
	<b>High</b>	106 (72.6%)	28 (19.2%)	12 (8.2%)	
<b>Leukocytosis</b>	<b>Moderate</b>	59 (74.7%)	18 (22.8%)	2 (2.5%)	0.089
	<b>High</b>	175 (72.3%)	43 (17.8%)	24 (9.9%)	

<b>SpO2</b>	<b>&lt;90</b>	188 (75.2%)	40 (16.0%)	22 (8.8%)	0.032
	<b>&gt;90</b>	46 (64.8%)	21 (29.6%)	4 (5.6%)	
<b>Fever</b>	<b>High</b>	71 (75.5%)	19 (20.2%)	4 (4.3%)	0.265
	<b>Very High</b>	163 (71.8%)	42 (18.5%)	22 (9.7%)	

188 **\*The percentages indicate proportion of patients within each category in any duration.**

189 Table 3 showed a significant association between the ICU residency duration and the infecting  
 190 isolates (P- value= 0.008). The patients suffering from fungal co-infection 126 (80.3%) stayed  
 191 fewer days in the ICU comparing with patients with bacterial co-infection 108 (65.9%).

192 Regarding therapy plan, there was a significant association between ICU residency duration and  
 193 the empirical antibiotics (P-value <0.001), patients administered ceftriaxone 182(81.6%) were  
 194 more likely to stay less at ICU compared with patients administered Ampicillin/Sulbactam 52  
 195 (53.1%). Patients who took fluconazole 69 (100%) were significantly more likely to stay less in the  
 196 ICU compared to those administered Piperacillin and Tazobactam with Levofloxacin or  
 197 Meropenem with Vancomycin 57 (50%), 108 (78.3%) respectively with P-value <0.001.

198 Moreover, patients administered iron supplements as part of their therapy regimen 199 (99%)  
 199 were significantly more likely to stay for a shorter duration of time compared with those who did  
 200 not administer iron 35 (29.2%, P-value <0.001).

201 **Table 3: Impact of Different Significant Values on The duration in the ICU.**

<b>Parameter</b>	<b>Duration 1-6 Days</b>	<b>Duration 7-11 Days</b>	<b>Death</b>	<b>P</b>
<b>Ampicillin/Sulbactam</b>	52 (53.1%) **	29 (29.6%)	17(17.3%)	

<b>Ceftriaxone</b>	182 (81.6%)	32 (14.3%)	9 (4.0%)	
				<.001
<b>Piperacillin/Tazobactam+ Levofloxacin</b>	57 (50.0%)	37 (32.5%)	20(17.5%)	
<b>Meropenem+ Vancomycin</b>	108 (78.3%)	24 (39.3%)	6 (4.3%)	
<b>Fluconazole</b>	69 (100%)	0 (0%)	0 (0%)	<.001
<b>Yes</b>	199 (99%)	0 (0%)	2 (1.0%)	
<b>Iron Supplement No</b>	35 (29.2%)	61 (50.8%)	24(20.0%)	<.001
<b>Fungi</b>	126 (80.3%)	24 (15.3%)	7 (4.5%)	
<b>Bacteria</b>	108 (65.9%)	37 (22.6%)	19(11.6%)	.008

202 **\*\* The percentages indicate proportion of patients within each category in any duration.**

203

## 204 Discussion

205 In this research, the characteristics of co-infection in 321 severely ill COVID-19 patients were  
 206 evaluated with a fatality rate of 8.1% in the ICU, compared to 25.7% mortality rate; that was  
 207 obtained from a systematic review of the emerging literature including 15 studies carried out in  
 208 countries most affected by the pandemic (16). Despite the absence of antimicrobial stewardship  
 209 in urgent response, the hospital's initiation of drastic empirical administration was crucial for  
 210 either prevention or treatment of suspected infections. Hospital's guideline adherence for  
 211 empiric antimicrobial therapy and the other drugs was effective.

212 COVID-19 patients are at risk of fungal infections during the latter stages of the disease; due to  
 213 seriously damaged alveoli and the decline in leukocyte counts (17). Based on the knowledge of  
 214 SARS in 2003 and the invasive Aspergillosis, it is vital to consider the possibility of accompanied

215 COVID and life-threatening fungal infection. At the beginning of blood/sputum culturing, the  
216 number of cases infected by *A.fumigatus* was 157. Initially, those patients were given empirical  
217 antibacterial regimens and in the ICU; because it was costly to be obtained by the hospital. By  
218 January, confirmed fungal infections were treated with Fluconazole. This had reduced the  
219 average ICU stay from six days to less than two days, and the mortality rate became 0% rather  
220 than 4.5% due to *A.fumigatus* invasive disease. Throughout the pandemic, specialists realized the  
221 risks of fungal co-infection. Therefore, the French High Council for Public Health recommended  
222 that clinicians should concentrate on fungal infections in COVID patients, particularly in severe  
223 cases of the disease.

224 Bacterial co-infection was recorded in 51.1% of cases, with higher mortality rates among  
225 Enterobacter infected patients; this may be due to its known drug resistance. It should be noted  
226 that normal oral flora colonization or contamination may occur, particularly in the sputum  
227 specimens. In general, the empirical treatment with Ceftriaxone or Ampicillin/Sulbactam showed  
228 minimal benefits to the clinical status. However, we observed a better prognosis with Ceftriaxone  
229 than Ampicillin/Sulbactam. The mortality rate also varied from 4% with Ceftriaxone vs. 17.3%  
230 with Ampicillin/Sulbactam; this association needs more investigation.

231 Once the bacterial co-infection is confirmed and the patient is admitted into the ICU, the wide-  
232 spectrum antimicrobial regimens are administered. Unfortunately, there is no available data to  
233 compare COVID-19 patients who received antibacterial agents with those who did not; to  
234 determine the therapeutic efficacy. However, Piperacillin with Tazobactam and Levofloxacin  
235 resemble Meropenem and Vancomycin in the clinical outcomes and management rate. Counter

236 to a study that reveals a higher rate of mortality and organ failure regarding Meropenem (13).  
237 Furthermore, after the recovery and discharge from the hospital, all outpatients have been  
238 prescribed Azithromycin, which also has antiviral activity and may decrease the incidence of  
239 acute organ failure (13).

240 Earlier examinations illustrated that multiple antibiotic administrations did not alter the disease  
241 results or had joined with higher deaths (18). In our study, it appeared to induce a good prognosis.  
242 Ceftriaxone, Meropenem, and vancomycin regimens have been linked with more favorable  
243 outcomes and lower mortality rates. Until solid evidence is available, antimicrobials should be  
244 maintained for critical cases and constantly re-evaluated based on the patient's progress. Most  
245 importantly, the therapy must only cover the suspected or confirmed bacterial infection.

246 Antibiotic resistance and allergic reactions are multifactorial issues, and the pandemic has  
247 frightened the health system and stimulated pressure on bacteria. In our study, all COVID-19  
248 patients were admitted to the ICU and received at least four diverse types of broad-spectrum  
249 antibacterial agents; in addition, the accessibility to over-the-counter antimicrobials had  
250 undeniably grown through the pandemic. This inappropriate behavior will lead to the evolution  
251 of high levels of resistant bacteria.

252 The unusual incidence of bacterial or fungal infections in our study differs from other published  
253 studies (9) (19). This significant finding is due to the participant characteristics of critically ill  
254 patients receiving therapy via invasive catheters and being at risk of infection by nosocomial  
255 pathogens. Moreover, the unusual rate of infection had been credited to the exhaustion in the

256 clinical care system creating a prolonged hospital exposure, principally in the major waves of the  
257 virus.

258 In our study, 100% of the patients were severe-critical ill. Therefore, it is required to differentiate  
259 between them and mild-moderate patients and prioritize the ICU admittance. Fever was the  
260 notable symptom in SARS-CoV-2 infection identified at the early stages of the disease. Regarding  
261 laboratory findings, leukocytosis occurred in critically ill patients with distinct grades, and it was  
262 observed in 11.4% severe COVID-19 cases (20); it aids in the disease progress evaluation. The  
263 intensity of leukocytosis reflects the strength of COVID-19 infection; it is exacerbated by the  
264 cytokine storm and inflammatory mediators that drive apoptosis and pulmonary microvascular  
265 destruction, creating alveolar oedema. The increased level of CRP is a diagnostic biomarker for  
266 coronavirus in distinguishing moderate and critical patients. The pathogenesis of COVID-19  
267 involves a vigorous inflammatory response that manages a dysregulated flood of immune cells  
268 and signaling molecules (21). In general, viral respiratory infections have been linked to hypoxia,  
269 but COVID-19 individually starts significantly low Oxygen saturation levels (<94%), while the  
270 normal SpO<sub>2</sub> is ≥95% at rest in healthy people. Hypoxia is a fearful condition that is monitored  
271 and adjusted by mechanical ventilation (22). Although several studies reported relations linking  
272 Laboratory findings and clinical outcomes, our cases did not show a significant link.

273 Throughout the coronavirus pandemic, the issue of tobacco smoking and the risk of infection  
274 were constantly reviewed. Published research indicated that smokers are twice as likely to  
275 develop severe COVID-19 as nonsmokers. Tobacco smoking induces alterations in the respiratory  
276 tract and cell-mediated immune response (23). Furthermore, current smokers have higher ace-2

277 gene expression than non-smokers; this gene is responsible for ACE-2 receptors production,  
278 which COVID-19 attaches to and penetrates the cells, thus raising the chance of infection (24).  
279 Our study did not find an association between smoking habits and the duration of ICU stay or  
280 clinical prognosis.

281 Numerous investigations found that older COVID-19 patients aged  $\geq 50$  years were correlated  
282 with higher risk for severe signs, atypical presentation, the opportunity for co-infections and  
283 higher fatality rates compared to patients with  $< 50$  years of age, and the rate usually increases  
284 rapidly with age; it is not surprising due to the drop in natural immunity by age, associated  
285 comorbidities and it is believed that older people are prone to adverse drug reactions. In general,  
286 people of different ages are prone to get infected with the COVID virus (25) (26). A review  
287 reported a twice higher fatality rate in males compared to females; it has stated that male  
288 patients may have higher ACE-2 enzyme activity, directed by male sex hormones, contributing to  
289 more risk for SARS-CoV-2 infection and worsening clinical outcomes (27). Additionally, the  
290 smoking rate is higher in males.

291 Effects of comorbidities such as hypertension, diabetes mellitus, coronary heart disease and  
292 Cancer were compared between survivors and non-survivors. All of those comorbid conditions  
293 have a significantly greater fatality rate in non-survivors; because they have decreased natural  
294 immunity and are poly-pharmacy patients (28) (29). In our study, there was no association  
295 between age, gender or comorbidities with the clinical outcomes and ICU stay duration.

296 Previous reports had described mild anemia in COVID-19 patients at the ICU; due to severe  
297 inflammation which consumes iron (30), the innate immune system limits the bioavailability of



298 iron; to diminish viral replication and infection. Accordingly, iron absorption from the diet is  
299 reduced, and the liver generates hepcidin which blocks carrying iron out of the cell. Accordingly,  
300 iron supplementation may exacerbate the disease and increase the inflammatory process (31).  
301 However, no solid investigations were performed on the relation between iron and clinical results  
302 in COVID-19 patients. In our study, 62.6% of the patients had received IV iron supplement for  
303 three days, based on a randomized clinical trials, and 99% of them had improved and stayed for  
304 a shorter time (1-6 days) in the ICU; which provided a good immunity enhancing. Therefore, there  
305 is a strong association between low serum levels of iron and an increased infection rate and  
306 morbidity.

307 COVID-19 produces oxidative stress irregularity, and this process has been enhanced by  
308 glutathione reduction. Thiones are synthesized in a multi-step process in which N-acetyl-cysteine  
309 is part of it. Thiones are also ACE-2 blockers, thereby diminishing SARS-CoV-2 penetration into  
310 the cell. In a placebo-controlled study, NAC administration had reduced plasma inflammatory  
311 biomarker levels via several mechanisms. Besides antioxidant activity, NAC has vasodilator  
312 activity, especially in the intravenous route. In addition, it has mucolytic properties, inhibits RNA  
313 virus replication, and has confirmed protective effects against comorbid conditions, including  
314 cardiovascular diseases (32). In our study, patients had received NAC 1200 mg/day during the  
315 hospital stay, and even after discharge, those showed a better prognosis and improvement in  
316 their health status.

317 This research has some limitations: first, it is a cross-sectional study holding obstacles restricting  
318 the potential bias and difficulty proofing the relation between the exposure and the outcome.

319 Other, it is a single-centre, and its results could vary in another setting. Comprehensively, those  
320 conclusions present data supporting a conservative antibiotic administration for severely unwell  
321 COVID-19 infected patients. Our examination regarding the impacts of employing antifungals to  
322 manage COVID-19 patients can work as a successful reference for future COVID-19 therapy.

### 323 **Conclusion**

324 The COVID-19 pandemic exerts pressure on healthcare professionals, including a high probability  
325 of infection. It is eminent to save lives during this pressure, even if it means multi-drug  
326 antimicrobial regimen usages for prevention or treatment. However, the insufficiency of data  
327 about antibiotic types and dosage, and duration of treatment through the pandemic continue to  
328 be challenging to health care providers. Bacterial and fungal co-infection is common among  
329 COVID-19 patients at the ICU in Palestine; it is not evident if these cases are attributed to SARS-  
330 CoV-2 or coincidental; little of available data. Finally, Antimicrobial stewardship, appropriate  
331 patient assessment, and selecting the appropriate antimicrobial agents for the right patient at  
332 the right time will decrease hospital stay, mortality, and health care costs.

333

### 334 **Acknowledgements:**

335 We would like to express our appreciation to the health worker at Beit-Jala Governmental  
336 Hospital, Palestine, for their support and cooperation.

### 337 **Availability of data and materials**

338 The data used to support the findings of this study are available from the corresponding author  
339 upon request

#### 340 **Ethics approval and consent to participate**

341 Ethical approval of the study was obtained from Birzeit University. The permission to use the  
342 generated data was obtained from Beit Jala Governmental Hospital laboratory administration.

#### 343 **Consent for publication**

344 All authors read and approved the final manuscript

#### 345 **Competing interests**

346 The authors declare that they have no Conflict of Interest

347

348

349

350

351

#### 352 **References**

- 353 1. Singhal T. 2020. A Review of Coronavirus Disease-2019 (COVID-19). Indian J  
354 Pediatr.
- 355 2. Miranda C, Silva V, Capita R, Alonso-Calleja C, Igrejas G, Poeta P. 2020.  
356 Implications of antibiotics use during the COVID-19 pandemic: Present and  
357 future. J Antimicrob Chemother 75.

- 358 3. Hendaus MA, Jomha FA. 2020. Covid-19 induced superimposed bacterial  
359 infection. *J Biomol Struct Dyn*.
- 360 4. Chaplin S. 2020. COVID -19: a brief history and treatments in development.  
361 *Prescriber* 31.
- 362 5. Morris DE, Cleary DW, Clarke SC. 2017. Secondary bacterial infections  
363 associated with influenza pandemics. *Front Microbiol*.
- 364 6. Huttner BD, Catho G, Pano-Pardo JR, Pulcini C, Schouten J. 2020. COVID-19:  
365 don't neglect antimicrobial stewardship principles! *Clin Microbiol Infect*.  
366 Elsevier B.V.
- 367 7. Karami Z, Knoop BT, Dofferhoff ASM, Blaauw MJT, Janssen NA, van  
368 Apeldoorn M, Kerckhoffs APM, van de Maat JS, Hoogerwerf JJ, ten Oever J.  
369 2021. Few bacterial co-infections but frequent empiric antibiotic use in the  
370 early phase of hospitalized patients with COVID-19: results from a  
371 multicentre retrospective cohort study in The Netherlands. *Infect Dis (Auckl)*  
372 53.
- 373 8. Prasetyoputri A. 2021. Detection of Bacterial Coinfection in COVID-19  
374 Patients Is a Missing Piece of the Puzzle in the COVID-19 Management in  
375 Indonesia. *ACS Infect Dis* 7.
- 376 9. Peng J, Wang Q, Mei H, Zheng H, Liang G, She X, Liu W. 2021. Fungal co-  
377 infection in COVID-19 patients : evidence from a systematic review and  
378 meta-analysis 13:7745–7757.
- 379 10. Prasso JE, Deng JC. 2017. Postviral Complications: Bacterial Pneumonia. *Clin*  
380 *Chest Med*.
- 381 11. Lucien MAB, Canarie MF, Kilgore PE, Jean-Denis G, Fénélon N, Pierre M,  
382 Cerpa M, Joseph GA, Maki G, Zervos MJ, Dely P, Boncy J, Sati H, Rio A del,  
383 Ramon-Pardo P. 2021. Antibiotics and antimicrobial resistance in the COVID-  
384 19 era: Perspective from resource-limited settings. *Int J Infect Dis*. Elsevier  
385 B.V.
- 386 12. Sieswerda E, de Boer MGJ, Bonten MMJ, Boersma WG, Jonkers RE, Aleva  
387 RM, Kullberg BJ, Schouten JA, van de Garde EMW, Verheij TJ, van der Eerden  
388 MM, Prins JM, Wiersinga WJ. 2021. Recommendations for antibacterial  
389 therapy in adults with COVID-19 – an evidence based guideline. *Clin*

- 390 Microbiol Infect.
- 391 13. Liu C, Wen Y, Wan W, Lei J, Jiang X. 2021. Clinical characteristics and  
392 antibiotics treatment in suspected bacterial infection patients with COVID-  
393 19. *Int Immunopharmacol* 90.
- 394 14. Pulia MS, Wolf I, Schulz LT, Pop-Vicas A, Schwei RJ, Lindenauer PK. 2020.  
395 COVID-19: An emerging threat to antibiotic stewardship in the emergency  
396 department. *West J Emerg Med*.
- 397 15. Abelenda-Alonso G, Padullés A, Rombauts A, Gudiol C, Pujol M, Alvarez-  
398 Pouso C, Jodar R, Carratalà J. 2020. Antibiotic prescription during the COVID-  
399 19 pandemic: A biphasic pattern. *Infect Control Hosp Epidemiol*.
- 400 16. Quah P, Li A, Phua J, Phua J. 2020. Mortality rates of patients with COVID-19 in  
401 the intensive care unit: A systematic review of the emerging literature. *Crit*  
402 *Care*. BioMed Central Ltd.
- 403 17. Song G, Liang G, Liu W. 2020. Fungal Co-infections Associated with Global  
404 COVID-19 Pandemic: A Clinical and Diagnostic Perspective from China.  
405 *Mycopathologia* 185:599–606.
- 406 18. Du Y, Tu L, Zhu P, Mu M, Wang R, Yang P, Wang X, Hu C, Ping R, Hu P, Li T,  
407 Cao F, Chang C, Hu Q, Jin Y, Xu G. 2020. Clinical features of 85 fatal cases of  
408 COVID-19 from Wuhan: A retrospective observational study. *Am J Respir Crit*  
409 *Care Med* 201:1372–1379.
- 410 19. Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H, Wu Y, Zhang L, Yu Z, Fang M, Yu T,  
411 Wang Y, Pan S, Zou X, Yuan S, Shang Y. 2020. Clinical course and outcomes  
412 of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a  
413 single-centered, retrospective, observational study. *Lancet Respir Med*  
414 8:475–481.
- 415 20. Frater JL, Zini G, d’Onofrio G, Rogers HJ. 2020. COVID-19 and the clinical  
416 hematology laboratory. *Int J Lab Hematol* 42:11–18.
- 417 21. Yamada T, Wakabayashi M, Yamaji T, Chopra N, Mikami T, Miyashita H,  
418 Miyashita S. 2020. Value of leukocytosis and elevated C-reactive protein in  
419 predicting severe coronavirus 2019 (COVID-19): A systematic review and  
420 meta-analysis. *Clin Chim Acta* 509:235–243.
- 421 22. Greenhalgh T, Knight M, Inda-Kim M, Fulop NJ, Leach J, Vindrola-Padros C.

- 422 2021. Remote management of covid-19 using home pulse oximetry and  
423 virtual ward support. *BMJ* 372.
- 424 23. Reddy RK, Charles WN, Sklavounos A, Dutt A, Seed PT, Khajuria A. 2021. The  
425 effect of smoking on COVID-19 severity: A systematic review and meta-  
426 analysis. *J Med Virol* 93:1045–1056.
- 427 24. Leung JM, Leung JM, Yang CX, Sin DD, Sin DD. 2020. “Current smoking is not  
428 associated with COVID-19.” *Eur Respir J* 55:8–10.
- 429 25. Zhang H, Wang X, Fu Z, Luo M, Zhang Z, Zhang K, He Y, Wan D, Zhang L,  
430 Wang J, Yan X, Han M, Chen Y. 2020. Potential Factors for Prediction of  
431 Disease Severity of COVID-19 Patients  
432 <https://doi.org/10.1101/2020.03.20.20039818>.
- 433 26. Gómez-Belda AB, Fernández-Garcés M, Mateo-Sanchis E, Madrazo M,  
434 Carmona M, Piles-Roger L, Artero A. 2021. COVID-19 in older adults: What  
435 are the differences with younger patients? *Geriatr Gerontol Int* 21:60–65.
- 436 27. Agrawal H, Das N, Nathani S, Saha S, Saini S, Kakar SS, Roy P. 2021. An  
437 Assessment on Impact of COVID-19 Infection in a Gender Specific Manner.  
438 *Stem Cell Rev Reports* 17:94–112.
- 439 28. Biswas M, Rahaman S, Biswas TK, Haque Z, Ibrahim B. 2021. Association of  
440 Sex, Age, and Comorbidities with Mortality in COVID-19 Patients: A  
441 Systematic Review and Meta-Analysis. *Intervirology* 64:36–47.
- 442 29. Qiu P, Zhou Y, Wang F, Wang H, Zhang M, Pan X, Zhao Q, Liu J. 2020. Clinical  
443 characteristics, laboratory outcome characteristics, comorbidities, and  
444 complications of related COVID-19 deceased: a systematic review and meta-  
445 analysis. *Aging Clin Exp Res* 32:1869–1878.
- 446 30. Baron DM, Franchini M, Goobie SM, Javidroozi M, Klein AA, Lasocki S,  
447 Liunbruno GM, Muñoz M, Shander A, Spahn DR, Zacharowski K, Meybohm  
448 P. 2020. Patient blood management during the COVID–19 pandemic: a  
449 narrative review. *Anaesthesia* 75:1105–1113.
- 450 31. Taneri PE, Gómez-Ochoa SA, Llanaj E, Raguindin PF, Rojas LZ, Roa-Díaz ZM,  
451 Salvador D, Groothof D, Minder B, Kopp-Heim D, Hautz WE, Eisenga MF,  
452 Franco OH, Glisic M, Muka T. 2020. Anemia and iron metabolism in COVID-  
453 19: a systematic review and meta-analysis. *Eur J Epidemiol* 35:763–773.

- 454 32. De Flora S, Balansky R, La Maestra S. 2020. Rationale for the use of N-  
455 acetylcysteine in both prevention and adjuvant therapy of COVID-19. FASEB  
456 J 34:13185–13193.

457